LGND
Ligand·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LGND
Ligand Pharmaceuticals Incorporated
A company that develops pharmaceuticals in the areas of oncology, central nervous system, inflammation, and blood disorders
555 Heritage Drive, Suite 200, Jupiter Florida 33458
--
Ligand Pharmaceuticals Incorporated was incorporated in Delaware in 1987 and is a biopharmaceutical company. The company's business model is to develop or acquire income-generating assets and integrate them into the cost structure of a lean enterprise. The company's goal is to create a sustainable and profitable business to generate shareholder value. Since the company's business model is based on cooperating with other pharmaceutical companies to commercialize and sell assets, a lot of the company's revenue comes from related royalties provided by partners. Recognizing the importance of drug reformulation in the pharmaceutical industry, the company added the CAPTISOL project to its technology investment in 2011. CAPTISOL is a powerful formulation technology with five U.S. Food and Drug Administration approved products, including Pfizer's VFEND IV and Baxter International's Nexterone, as well as several other partner programs that are in clinical use. Compared with other companies in the same industry, the company has formed the largest industry-diversified asset portfolio, which can generate significant returns in the future. Therapeutics developed in the portfolio can address many unaddressed gaps in medical needs, including hepatitis, muscle atrophy, Alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis, and osteoporosis.
Earnings Call
Q1/2025
Estimate EPS1.21
Actual EPS1.33
Estimate Revenue37.84M
Actual Revenue45.33M
Ligand Pharmaceuticals' Q1 2025: Unpacking Contradictions in Investment Strategy, Product Launches, and Revenue Expectations
May 19,2025 11:44
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.42
Actual EPS1.6
Estimate Revenue43.87M
Actual Revenue47.63M
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics
Aug 10,2025 04:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LGND has released its 2025 Q3 earnings. EPS was reported at 3.09, versus the expected 1.89, beating expectations. The chart below visualizes how LGND has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LGND has released its 2025 Q3 earnings report, with revenue of 115.46M, reflecting a YoY change of 122.85%, and net profit of 117.27M, showing a YoY change of 1735.15%. The Sankey diagram below clearly presents LGND's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
